CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy

Debra L. Richardson, Leigh G. Seamon, Matthew J. Carlson, David M. O'Malley, Jeffrey M. Fowler, Larry J. Copeland, David E. Cohn

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: To compare the slope of CA125 decline in patients with optimally debulked epithelial ovarian cancer achieving a response to intravenous (IV) versus intraperitoneal (IP) platinum-based chemotherapy. The secondary objectives are to determine if the time to normal CA125 levels and time to nadir of CA125 differ between the groups. Methods: Patients with primary stage III, optimally cytoreduced ovarian cancer were stratified as to whether platinum and taxane chemotherapy was administered entirely IV (IV group), or whether it was given IV and IP (IP group). Inclusion criteria included an elevated CA125 prior to surgery or first cycle chemotherapy and at least 1 month follow-up after completion of chemotherapy. All patients had a complete or partial response. In addition, IP patients had to have received at least 1 cycle of IP chemotherapy. Because of the large range of CA125 levels, raw CA125 values were natural log transformed and compared using repeated measures analysis of variance (ANOVA). Results: 53 patients met inclusion criteria, 36 in the IV arm and 17 in the IP arm. The median number of chemotherapy cycles was 6 in both groups; the range was 5-9 in the IP arm and 6-10 in the IV arm. The median CA125 prior to surgery was 888 (range 45-5940) in the IP group and 1081 (range 58-19,440) in the IV group, p = 0.55. After surgery but prior to chemotherapy, the median CA125 was 175.5 in the IP arm (range 10.8-4035) versus 233.5 (range 16.5-6890) in the IV arm, p = 0.43. The median time to normalization of CA125 for the IP group was half the time of the IV group, 0.75 months (range 0 to 4.5) versus 1.5 months (range 0 to 6.25), p = 0.15. The time to nadir was slightly faster in the IP arm as compared to the IV arm, 4.5 months (2-10.5) versus 6 months (2-14), p = 0.13. The CA125 slopes were parallel, indicating that the CA125 levels declined at the same rate in both groups. However, the patients treated with IP chemotherapy had significantly lower CA125 levels over all the cycles, p = 0.02. Conclusions: Contrary to the assumption that IP chemotherapy elevates CA125 levels due to peritoneal irritation, these results show a trend towards faster time to CA125 normalization and nadir, and significantly lower CA125 levels during therapy for patients responding to IP chemotherapy compared with patients responding to IV therapy.

Original languageEnglish (US)
Pages (from-to)233-236
Number of pages4
JournalGynecologic Oncology
Volume111
Issue number2
DOIs
StatePublished - Nov 2008

Fingerprint

Platinum
Ovarian Neoplasms
Drug Therapy
Analysis of Variance
Therapeutics

Keywords

  • CA 125
  • CA-125
  • CA125
  • Intraperitoneal chemotherapy
  • Ovarian cancer
  • Platinum chemotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. / Richardson, Debra L.; Seamon, Leigh G.; Carlson, Matthew J.; O'Malley, David M.; Fowler, Jeffrey M.; Copeland, Larry J.; Cohn, David E.

In: Gynecologic Oncology, Vol. 111, No. 2, 11.2008, p. 233-236.

Research output: Contribution to journalArticle

Richardson, Debra L. ; Seamon, Leigh G. ; Carlson, Matthew J. ; O'Malley, David M. ; Fowler, Jeffrey M. ; Copeland, Larry J. ; Cohn, David E. / CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. In: Gynecologic Oncology. 2008 ; Vol. 111, No. 2. pp. 233-236.
@article{d789e1d79b964f56af4be9a3fc413754,
title = "CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy",
abstract = "Objectives: To compare the slope of CA125 decline in patients with optimally debulked epithelial ovarian cancer achieving a response to intravenous (IV) versus intraperitoneal (IP) platinum-based chemotherapy. The secondary objectives are to determine if the time to normal CA125 levels and time to nadir of CA125 differ between the groups. Methods: Patients with primary stage III, optimally cytoreduced ovarian cancer were stratified as to whether platinum and taxane chemotherapy was administered entirely IV (IV group), or whether it was given IV and IP (IP group). Inclusion criteria included an elevated CA125 prior to surgery or first cycle chemotherapy and at least 1 month follow-up after completion of chemotherapy. All patients had a complete or partial response. In addition, IP patients had to have received at least 1 cycle of IP chemotherapy. Because of the large range of CA125 levels, raw CA125 values were natural log transformed and compared using repeated measures analysis of variance (ANOVA). Results: 53 patients met inclusion criteria, 36 in the IV arm and 17 in the IP arm. The median number of chemotherapy cycles was 6 in both groups; the range was 5-9 in the IP arm and 6-10 in the IV arm. The median CA125 prior to surgery was 888 (range 45-5940) in the IP group and 1081 (range 58-19,440) in the IV group, p = 0.55. After surgery but prior to chemotherapy, the median CA125 was 175.5 in the IP arm (range 10.8-4035) versus 233.5 (range 16.5-6890) in the IV arm, p = 0.43. The median time to normalization of CA125 for the IP group was half the time of the IV group, 0.75 months (range 0 to 4.5) versus 1.5 months (range 0 to 6.25), p = 0.15. The time to nadir was slightly faster in the IP arm as compared to the IV arm, 4.5 months (2-10.5) versus 6 months (2-14), p = 0.13. The CA125 slopes were parallel, indicating that the CA125 levels declined at the same rate in both groups. However, the patients treated with IP chemotherapy had significantly lower CA125 levels over all the cycles, p = 0.02. Conclusions: Contrary to the assumption that IP chemotherapy elevates CA125 levels due to peritoneal irritation, these results show a trend towards faster time to CA125 normalization and nadir, and significantly lower CA125 levels during therapy for patients responding to IP chemotherapy compared with patients responding to IV therapy.",
keywords = "CA 125, CA-125, CA125, Intraperitoneal chemotherapy, Ovarian cancer, Platinum chemotherapy",
author = "Richardson, {Debra L.} and Seamon, {Leigh G.} and Carlson, {Matthew J.} and O'Malley, {David M.} and Fowler, {Jeffrey M.} and Copeland, {Larry J.} and Cohn, {David E.}",
year = "2008",
month = "11",
doi = "10.1016/j.ygyno.2008.07.035",
language = "English (US)",
volume = "111",
pages = "233--236",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy

AU - Richardson, Debra L.

AU - Seamon, Leigh G.

AU - Carlson, Matthew J.

AU - O'Malley, David M.

AU - Fowler, Jeffrey M.

AU - Copeland, Larry J.

AU - Cohn, David E.

PY - 2008/11

Y1 - 2008/11

N2 - Objectives: To compare the slope of CA125 decline in patients with optimally debulked epithelial ovarian cancer achieving a response to intravenous (IV) versus intraperitoneal (IP) platinum-based chemotherapy. The secondary objectives are to determine if the time to normal CA125 levels and time to nadir of CA125 differ between the groups. Methods: Patients with primary stage III, optimally cytoreduced ovarian cancer were stratified as to whether platinum and taxane chemotherapy was administered entirely IV (IV group), or whether it was given IV and IP (IP group). Inclusion criteria included an elevated CA125 prior to surgery or first cycle chemotherapy and at least 1 month follow-up after completion of chemotherapy. All patients had a complete or partial response. In addition, IP patients had to have received at least 1 cycle of IP chemotherapy. Because of the large range of CA125 levels, raw CA125 values were natural log transformed and compared using repeated measures analysis of variance (ANOVA). Results: 53 patients met inclusion criteria, 36 in the IV arm and 17 in the IP arm. The median number of chemotherapy cycles was 6 in both groups; the range was 5-9 in the IP arm and 6-10 in the IV arm. The median CA125 prior to surgery was 888 (range 45-5940) in the IP group and 1081 (range 58-19,440) in the IV group, p = 0.55. After surgery but prior to chemotherapy, the median CA125 was 175.5 in the IP arm (range 10.8-4035) versus 233.5 (range 16.5-6890) in the IV arm, p = 0.43. The median time to normalization of CA125 for the IP group was half the time of the IV group, 0.75 months (range 0 to 4.5) versus 1.5 months (range 0 to 6.25), p = 0.15. The time to nadir was slightly faster in the IP arm as compared to the IV arm, 4.5 months (2-10.5) versus 6 months (2-14), p = 0.13. The CA125 slopes were parallel, indicating that the CA125 levels declined at the same rate in both groups. However, the patients treated with IP chemotherapy had significantly lower CA125 levels over all the cycles, p = 0.02. Conclusions: Contrary to the assumption that IP chemotherapy elevates CA125 levels due to peritoneal irritation, these results show a trend towards faster time to CA125 normalization and nadir, and significantly lower CA125 levels during therapy for patients responding to IP chemotherapy compared with patients responding to IV therapy.

AB - Objectives: To compare the slope of CA125 decline in patients with optimally debulked epithelial ovarian cancer achieving a response to intravenous (IV) versus intraperitoneal (IP) platinum-based chemotherapy. The secondary objectives are to determine if the time to normal CA125 levels and time to nadir of CA125 differ between the groups. Methods: Patients with primary stage III, optimally cytoreduced ovarian cancer were stratified as to whether platinum and taxane chemotherapy was administered entirely IV (IV group), or whether it was given IV and IP (IP group). Inclusion criteria included an elevated CA125 prior to surgery or first cycle chemotherapy and at least 1 month follow-up after completion of chemotherapy. All patients had a complete or partial response. In addition, IP patients had to have received at least 1 cycle of IP chemotherapy. Because of the large range of CA125 levels, raw CA125 values were natural log transformed and compared using repeated measures analysis of variance (ANOVA). Results: 53 patients met inclusion criteria, 36 in the IV arm and 17 in the IP arm. The median number of chemotherapy cycles was 6 in both groups; the range was 5-9 in the IP arm and 6-10 in the IV arm. The median CA125 prior to surgery was 888 (range 45-5940) in the IP group and 1081 (range 58-19,440) in the IV group, p = 0.55. After surgery but prior to chemotherapy, the median CA125 was 175.5 in the IP arm (range 10.8-4035) versus 233.5 (range 16.5-6890) in the IV arm, p = 0.43. The median time to normalization of CA125 for the IP group was half the time of the IV group, 0.75 months (range 0 to 4.5) versus 1.5 months (range 0 to 6.25), p = 0.15. The time to nadir was slightly faster in the IP arm as compared to the IV arm, 4.5 months (2-10.5) versus 6 months (2-14), p = 0.13. The CA125 slopes were parallel, indicating that the CA125 levels declined at the same rate in both groups. However, the patients treated with IP chemotherapy had significantly lower CA125 levels over all the cycles, p = 0.02. Conclusions: Contrary to the assumption that IP chemotherapy elevates CA125 levels due to peritoneal irritation, these results show a trend towards faster time to CA125 normalization and nadir, and significantly lower CA125 levels during therapy for patients responding to IP chemotherapy compared with patients responding to IV therapy.

KW - CA 125

KW - CA-125

KW - CA125

KW - Intraperitoneal chemotherapy

KW - Ovarian cancer

KW - Platinum chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=55649121371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649121371&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.07.035

DO - 10.1016/j.ygyno.2008.07.035

M3 - Article

VL - 111

SP - 233

EP - 236

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -